Intellia departs Regeneron deal: The CRISPR biotech disclosed Friday that it had opted out of a partnership with Regeneron to develop a factor IX gene editing therapy. The partners had penned the deal in 2020, which made Intellia responsible for 35% of development costs in exchange for 35% of profits.
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Is Intellia Therapeutics Stock a Buy Now
On track to dose the first patient in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy in Q1 2024Expect to initiate the Phase 3 study...
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based...
Data reinforce the potential of NTLA-2002 to eliminate angioedema attacks in people living with hereditary angioedema (HAE) after a single dose A single dose of NTLA-2002 led to 95% mean reduction in...
Intellia Therapeutics announced Thursday that it is cutting 15% of its workforce and pausing certain research programs following an internal review.
Core priorities through 2026 include completion of Phase 3 study and BLA submission for NTLA-2002, completion of patient enrollment in the pivotal study of NTLA-2001, clinical validation of modular in...
Intellia Therapeutics is the latest gene editing biotech to downsize following a dismal year for the industry.